Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

MISTRAS Group Inc (NYSE:MG) is set to release its Q4 2024 earnings on Mar 5, 2025. The consensus estimate for Q4 2024 revenue ...

For each additional point on the MG-ADL scale, the rate of exacerbations increased by 13%. In the MGFA patient registry study, MG-ADL scores were higher among patients who were female, younger ...

Dynamical insights from magnetohydrodynamic simulations First Author: Gourab GiriAuthors: Joydeep Bagchi, Kshitij Thorat, ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

A new report looks at popular fast-food chains, ranking their fries based on calories, fat, sugar, and sodium, identifying ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.